News and Trends 12 Jul 2023 Crossbow Therapeutics launches with $80M to target cancer Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, has announced an $80 million Series A funding. The round was led by MPM BioImpact and Pfizer Ventures, with participation from Polaris Partners, BVF Partners, Eli Lilly and Company, Mirae Asset Venture […] July 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 11 Jul 2023 AIS Biotech: startup employs carbohydrates to fight the flu Keen on discovering novel ways to tackle viral infections, AIS Biotech, a French company based in the Alps, aims to combat influenza, more commonly known as the flu, by leveraging the medicinal promise behind glycobiotechnology. A field that has been gaining momentum over the past decade, glycobiotechnology is the study of complex carbohydrates which has […] July 11, 2023 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2023 Immune memory research could lead to next generation of epigenetic drugs A team of researchers has discovered that the memory of the immune system relies on characteristic epigenetic features and a specific 3D arrangement of the DNA in the nucleus of memory cells, allowing for a fast activation of these cells. These features are altered in chronic inflammation diseases like asthma and could be important in […] July 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2023 NodThera first to show reduction in neuroinflammation with inflammasome inhibitor NodThera has announced positive, initial data from four subjects in the elderly volunteer stage of its phase Ib/IIa study evaluating the effects of its lead candidate NT-0796 on inflammatory and disease-specific biomarkers in the blood and cerebrospinal fluid (CSF). NodThera is a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. Alan […] July 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2023 NK:IO awarded £1.6M grant to develop NK cell therapy NK:IO, a U.K. company working on natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumors, has been awarded £1.6 million ($2.1 million) in grant funding from Innovate UK’s New Cancer Therapeutics program. The funding will support preclinical development, including development of a manufacturing process in collaboration […] July 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 11 Jul 2023 Unlocking the power of mRNA technology By Yochi Slonim, CEO and co-founder of Anima Biotech mRNA technology has gained widespread recognition due to its role in the development of vaccines, such as those used against COVID-19; however, the scope of mRNA extends far beyond vaccines, offering a range of applications for addressing different conditions. Vaccines represent a notable application of mRNA […] July 11, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2023 Inhaled mRNA medicines redefine respiratory disease treatment By Carsten Rudolph, co-founder and CEO of Ethris Advancements in mRNA technology have led to the development of inhaled mRNA medicines, which hold tremendous potential for revolutionizing the treatment of respiratory diseases, an area with high unmet needs. However, the primary hurdle in its clinical application lies in the identification of a delivery system that […] July 11, 2023 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Jul 2023 Lung cancer research: five advancements over the past year Lung cancer is the second most common cancer worldwide, with more than 2.2 million new cases of lung cancer being reported in 2020. Survival rates depend on the stage of diagnosis, and, according to statistics from Cancer Research UK, in England, more than 55% of people with stage 1 lung cancer survive for five years […] July 10, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2023 Existing cancer drug could be repurposed to fight certain aggressive cancers A team of scientists led by Nanyang Technological University, Singapore (NTU Singapore) has found that an existing cancer drug could be repurposed to target a subset of cancers that currently lack targeted treatment options and is often associated with poor outcomes.This subset of cancers makes up 15% of all cancers and is especially prevalent in […] July 10, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 10 Jul 2023 “Ready-to-use” enzymatically produced cell-free synthetic DNA in mRNA manufacturing By Ashish Dhir, PhD and Amy Walker, PhD, 4basebio The pace, efficacy and scalability with which the success of mRNA vaccines against COVID-19 was demonstrated opened endless possibilities for mRNA medicine in broad areas of infectious diseases, cancers, protein-encoding replacement therapies. The advantages of RNA medicine are obvious, with the ease and speed of design […] July 10, 2023 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 10 Jul 2023 Making an impact through targeting mRNA Biotech company Molecure develops small molecule therapies that can regulate RNA and underexplored protein targets for the treatment of incurable diseases, including cancer and fibrotic and inflammatory diseases. The company, which was named as one of our 10 biotech companies leading the charge in Poland, told Labiotech that its RNA platform finds small molecules that […] July 10, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 10 Jul 2023 Unleashing the potential: Optimizing mRNA for the discovery of transformative medicines By Dr. Alexander Zehnder, CEO, CureVac The success of mRNA vaccines in COVID-19 propelled the role of this new modality to the forefront of medicine. Not only are new prophylactic mRNA vaccines for various respiratory diseases advancing through clinical development, but mRNA medicines are now being developed in many wide-ranging applications, including cancer and rare […] July 10, 2023 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email